November 14, 2011
SymBio Pharmaceuticals LimitedFuminori Yoshida
Representative Director
President and Chief Executive Officer

Clinical Trial Notification Accepted for SymBio’s Japan Phase 2 Trialof Bendamustine HCl (SyB L-0501) in Multiple Myeloma
TOKYO, Japan, November 14, 2011 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, President &CEO: Fuminori Yoshida, “SymBio”) announced that clinical trial notification (CTN)1 has been accepted for its
phase 2 clinical trial using bendamustine hydrochloride (SyB L-0501) in refractory and relapsed multiple
myeloma2 (MM) patients.
In Japan, SymBio received marketing approval of TREAKISYM® (SyB L-0501) in October, 2010, for thetreatment of patients with refractory/relapsed low-grade non-Hodgkin’s lymphoma3 and MM. Working with
Eisai Co. Ltd., TREAKISYM® is expected to achieve rapid market penetration in Japan.

Regarding SyB L-0501 development in MM, SymBio has a second phase 2 clinical trial in frontline MM(untreated patients), but plans to prioritize development in refractory and relapsed MM (patients previously
treated with other oncology drugs) due to the existence of higher unmet medical needs.

SymBio has also initiated phase 2 trials for SyB L-0501 in refractory/relapsed intermediate and high-grade
non-Hodgkin’s lymphoma, as well as in frontline low-grade non-Hodgkin’s lymphoma patients. The Company
continues to pursue other indications for TREAKISYM® in the hematology space as nimbly as possible inorder to maximize the potential of this ‘pipeline within a molecule’ and address other unmet medical needs inpatients.

SymBio’s financial forecast for FY 2011 will not be revised due to the acceptance of clinical trial notification.

[Please read the following to learn more about Glossary, Bendamustine Hydrochloride (SyB L-0501),and SymBio Pharmaceuticals][Contact]Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125

Note to Editors

Glossary
1 CTN: Equivalent to the IND in US
2 Multiple Myeloma: is a hematological cancer in which there is malignant proliferation of abnormal plasma cells that
populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonalantibody that replaces normal antibodies in the blood, thereby increasing susceptibility to infection and renal failure.
Symptoms include pain, anemia, weakness, bone fractures, and neurological symptoms. It is considered a progressive
and incurable disease; the number of multiple myeloma patients in Japan is estimated to be around 13,000. The numberof Refractory/relapsed and frontline patients will be almost same.
3 Non-Hodgkin’s lymphoma: is cancer of the lymphoid tissue, which includes the lymph nodes, spleen, and otherorgans of the immune system, and is the most common form of lymphoma in Japan. Most lymphomas start in a type ofwhite blood cells called B lymphocytes, or B cells. For most patients, the cause of this cancer is unknown, but lymphomas
may develop in people with weakened immune systems. There are many different types of non-Hodgkin's lymphoma. It isclassified according to how fast the cancer spreads. The cancer may be low grade (slow growing), intermediate grade, orhigh grade (fast growing). According to the American Cancer Society, a person has a 1 in 50 chance of developingnon-Hodgkin's lymphoma. The number of low-grade non-Hodgkin’s lymphoma1 patients in Japan is estimated to bearound 11,000, including 4,000 refractory/relapsed patients and 7,000 untreated patients.

About Bendamustine Hydrochloride (SyB L-0501))
Bendamustine was first synthesized in the early 1960s in former ‘East Germany’ by Jenapharm, and iscurrently marketed in Germany under the brand name “Ribomustin®” as a treatment for non-Hodgkin’s
lymphoma, multiple myeloma and chronic lymphocytic leukemia. Mundipharma has received market
authorization in a number of EU countries for bendamustine under the brand name “Levact®.” In the UnitedStates, the drug has been approved by the U.S. Food and Drug Administration and is marketed asTREANDA® for the treatment of chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin'slymphoma. SymBio Pharmaceuticals Limited originally acquired the exclusive right from Astellas DeutschlandGmbH (Headquarters: Munich, Germany, formerly Astellas Pharma GmbH) to develop and commercialize
bendamustine in Japan (December, 2005), followed by signature of a second license agreement for theexclusive right to China/Hong Kong, Taiwan, South Korea and Singapore (March, 2007).
1. About TREAKISYM®
Product Name:
TREAKISYM® for Injection, for intravenous infusion 100 mg
Generic Name:bendamustine hydrochloride
Indications and Usage:
For the treatment of relapsed or refractory forms of the following indications:・ Low-grade B-cell non-Hodgkin’s lymphoma
・ Mantle cell lymphoma
Dosage and Administration:
The standard adult dose of bendamustine hydrochloride is 120 mg/m2 infused
intravenously over 60 minutes on Days 1 and 2 of repeated 21-day cycles. The dose maybe reduced as deemed appropriate according to the patient’s condition.

2. About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previouslyserved concurrently as Corporate VP of Amgen Ltd. and founding President of Amgen Japan (currentlyTakeda Bio Development Center Limited). The company’s underlying corporate mission is “delivering
hope to patients in need” as it aspires to be a leading specialty pharmaceutical company in Asia Pacificdedicated to addressing underserved medical needs in the areas of oncology, hematology andautoimmune disease.